Robert Sverdlin

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier et al. · JAMA Oncology · 2021 · 81 citations · Full text

Medicine, Gynecology, Oncology +17

Docetaxel–cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

M. Spielmann, Laurent Zelek, Robert Sverdlin et al. · Annals of Oncology · 1999 · 34 citations · Full text

Medicine, Oncology, Pharmacology +12

EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

Claire Falandry, Aude Marie Savoye, Laëtitia Stefani et al. · Journal of Clinical Oncology · 2019 · 27 citations

Medicine, Gynecology, Oncology +17

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Raphaël Leman, Etienne Müller, Angélina Legros et al. · Clinical Cancer Research · 2023 · 26 citations · Full text

Medicine, Gynecology, Oncology +17